Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
Burosumab-treated patients had significantly higher serum phosphate and 1,25-dihydroxyvitamin D levels, and nonsignificantly lower alkaline phosphatase levels, compared with patients not treated with burosumab.
Source: Abstract. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Study design awaiting verification.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.
Meta-analysis unclear · Blinding unclear / not reported · Research setting awaiting verification
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Real-world outcomes in patients with tumor-induced osteomalacia treated vs not treated with burosumab
Study design awaiting verification · Journal of the Endocrine Society · 2026
Original publication title
Real-world outcomes in patients with tumor-induced osteomalacia treated vs not treated with burosumab
© The Author(s) 2026. Published by Oxford University Press on behalf of the Endocrine Society.
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: What objectives does the paper state?
This study compares clinical and patient-reported outcomes in patients with TIO treated vs not treated with burosumab in a real-world setting.
Source: ObjectiveAbstract: Context
Tumor-induced osteomalacia (TIO) is an ultra-rare condition caused by tumors secreting fibroblast growth factor-23, leading to chronic hypophosphatemia, pain, muscle weakness, fractures, and impaired physical function. Burosumab is a monoclonal antibody indicated for treatment of TIO when tumors cannot be curatively resected.
Source: ContextAbstract: Design
This interim analysis reports outcomes at enrollment in the prospective, observational Tumor-Induced Osteomalacia Disease Monitoring Program (NCT04783428), stratified by burosumab treatment status at enrollment.
Source: DesignAbstract: Setting
Tertiary care centers in the United States and Argentina.
Source: SettingAbstract: Patients
Patients with TIO from the Disease Monitoring Program.
Source: PatientsAbstract: Exposure
Burosumab treatment.
Source: ExposureAbstract: Main outcome measure(s)
Biochemistry measurements and patient-reported health-related quality of life (pain, fatigue, and physical function).
Source: Main outcome measure(s)Abstract: Results
21 patients with TIO (61.9% female, median [Q1, Q3] age 49.7 years [41.6, 57.3]) were included. At enrollment, 11 (52.4%) patients were treated with burosumab, for a median (Q1, Q3) duration of 4.1 years (0.8, 7.0). Burosumab-treated patients had significantly higher serum phosphate and 1,25-dihydroxyvitamin D levels, and nonsignificantly lower alkaline phosphatase levels, compared with patients not treated with burosumab. Patients treated with burosumab reported significantly lower median Brief Pain Inventory scores, nonsignificantly lower Brief Fatigue Inventory scores, and nonsignificantly higher Patient-Reported Outcomes Measurement Information System Physical Function and Short-Form-36 scores, indicating lower symptom severity and better health-related quality of life.
Source: ResultsAbstract: Conclusion
This study suggests favorable biochemical and patient-reported outcomes in patients with TIO treated with burosumab.
Source: ConclusionAuthors’ abstract
Abstract
Context
Tumor-induced osteomalacia (TIO) is an ultra-rare condition caused by tumors secreting fibroblast growth factor-23, leading to chronic hypophosphatemia, pain, muscle weakness, fractures, and impaired physical function. Burosumab is a monoclonal antibody indicated for treatment of TIO when tumors cannot be curatively resected.
Objective
This study compares clinical and patient-reported outcomes in patients with TIO treated vs not treated with burosumab in a real-world setting.
Design
This interim analysis reports outcomes at enrollment in the prospective, observational Tumor-Induced Osteomalacia Disease Monitoring Program (NCT04783428), stratified by burosumab treatment status at enrollment.
Setting
Tertiary care centers in the United States and Argentina.
Patients
Patients with TIO from the Disease Monitoring Program.
Exposure
Burosumab treatment.
Main outcome measure(s)
Biochemistry measurements and patient-reported health-related quality of life (pain, fatigue, and physical function).
Results
21 patients with TIO (61.9% female, median [Q1, Q3] age 49.7 years [41.6, 57.3]) were included. At enrollment, 11 (52.4%) patients were treated with burosumab, for a median (Q1, Q3) duration of 4.1 years (0.8, 7.0). Burosumab-treated patients had significantly higher serum phosphate and 1,25-dihydroxyvitamin D levels, and nonsignificantly lower alkaline phosphatase levels, compared with patients not treated with burosumab. Patients treated with burosumab reported significantly lower median Brief Pain Inventory scores, nonsignificantly lower Brief Fatigue Inventory scores, and nonsignificantly higher Patient-Reported Outcomes Measurement Information System Physical Function and Short-Form-36 scores, indicating lower symptom severity and better health-related quality of life.
Conclusion
This study suggests favorable biochemical and patient-reported outcomes in patients with TIO treated with burosumab.
Publication and source details
Original title: Real-world outcomes in patients with tumor-induced osteomalacia treated vs not treated with burosumab
María Belén Zanchetta; Kathryn M Dahir; Erik A Imel; Thomas O Carpenter; Kerry Sandilands; Ben Johnson; Zhiyi Li; Lucinda Camidge; Elke Rottier; Emma Wilkes; Emily Vinall; Soraya Sader; Suzanne M Jan de Beur
Journal of the Endocrine Society · 2026
Correspondence: Emily Vinall, MChem, Real World Evidence, Adelphi Real World, Bollington SK10 5JB, UK. Email: emily.vinall@omc.com.© The Author(s) 2026. Published by Oxford University Press on behalf of the Endocrine Society.2026https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. See the journal About page for additional terms. Kyowa Kirin & Ultragenyx10.13039/501100004095Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-10T22:02:37.052265+00:00
DOI: 10.1210/jendso/bvag165 · PMC13453538